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Medulloblastoma and ependymoma account for about
30% of all newly diagnosed brain tumours in children.
As curative treatment options are available since many
years, our attention has to focus on late eﬀects in sur-
vivors of brain tumours. Neurocognitive sequelae are of
concern and more rarely development of secondary
tumours.
We report on a 37-year-old patient who was treated
23 years earlier for a large supratentorial right temporo-
occipital ependymoma (8 · 7 · 5 cm). This ependy-
moma was cured with gross-total resection, involved
ﬁeld radiation (54Gy, conventional fractionation) and
maintenance chemotherapy (VM-26 and CCNU) for
1 year. After a latency period of more than 20 years an
undiﬀerentiated sarcoma with a high proliferation-index
(Figure 1a, b) developed in the previously irradiated
ﬁeld involving skull and scalp (Figure 2a). A complete
remission of this secondary malignant tumour could be
obtained by subtotal surgery followed by seven cycles of
epirubicin and ifosfamide (Figure 2b). Our patient
experiences good quality of life, 18 months after diag-
nosis of his secondary tumour. He runs his own toy-
shop, is able to drive a car and has normal social con-
tacts. Neuropsychological assessment after his last
treatment revealed left sided neglect and minor learning
deﬁcits for visual patterns.
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Figure 2. MRI obtained at diagnosis of a secondary tumour in the
previously irradiated ﬁeld (a). Complete remission 16 months later
after subtotal resection of an undiﬀerentiated sarcoma and seven cycles
of epirubicin and ifosfamide (b).
Figure 1. H&E staining (scale bar 50 lm) depicting undiﬀerentiated
sarcoma (FNCLCC grade 3) Moderately to highly cellular tumour
consisting of pleomorphic undiﬀerentiated often spindle shaped neo-
plastic cells with frequent mitosis and a proliferative index of up to
60% (a). Large areas of necrosis (<50% of total specimen).
Immunohistochemically tumour cells positive for MyoD1 (b) and ne-
gative for EMA, CD34, CD99, desmin, smooth muscle alpha-actin,
myogenin and cytokeratins. Staining for glial ﬁbrillary acidic protein
(GFAP) and S-100 only labelled reactive astrocytes.
Journal of Neuro-Oncology (2005) 72: 239  Springer 2005
DOI 10.1007/s11060-005-3278-1
